DELAWARE, March 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that iQ-008, a novel analgesic compound, demonstrates efficacy in in vivo studies. Developed as a therapeutic for neuropathic pain, iQ-008 shows significant effectiveness in all pain models.
A rationally designed, multi-targeting compound, iQ-008 presented a better-than-standard profile in preclinical efficacy screenings. “This is very good news and an important step in the development of iQ-008 as a promising therapeutic,” said iQure Chief Executive Officer Pawel Zolnierczyk. “The results of efficacy after oral dosing are a further indication that iQ‑008 will be viable in capsule or tablet form in human studies. We are encouraged by successful in vivo studies with the data confirming that iQ-008 meets the criteria for the Lipinski/Pfizer Rule of Five.”
Lipinski’s Rule of Five, also known as Pfizer’s Rule of Five, is a critical indicator for drug development programs that help identify successful drug candidates. The rules identify candidates likely to have a desired profile on intestinal permeability and aqueous solubility, which is an indication for oral absorption.
Earlier this year, iQure secured global patent protection (including the US, Europe, China and Canada) for iQ-008, following results showing efficacy in outperforming standards of care.
About iQure Pharma
iQure Pharma is a global biotech firm headquartered in the US, focused on the development of new therapeutics for neuropathic pain. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr Anna Rzewuska at firstname.lastname@example.org.